NCCN Guidelines® Insights - Bladder Cancer, Version 5.2018
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.
This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Bladder Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Bladder Cancer
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Thomas W. Flaig, MD, Panel Chair, has disclosed that he receives grant/research support from Agensys, Inc.; Aragon Pharmaceuticals Inc.; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; BN ImmunoTherapeutics, Inc.; Bristol-Myers Squibb Company; Dendreon Corporation; Eli Lilly and Company; Exelixis Inc.; Genentech, Inc.; GTx, Inc.; Janssen Pharmaceutica Products, LP; Janssen/Cougar; Medivation, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Laboratories, Inc.; Roche/Genentech; sanofi-aventis U.S.; Seattle Genetics; SOTIO, LLC; and Tokai Pharmaceuticals, Inc. He has ownership/partnership/principal in Aurora Oncology, and has received consulting fees/honoraria from BN ImmunoTherapeutics, Inc. and GTx, Inc.
Philippe E. Spiess, MD, MS, Panel Vice Chair, has disclosed that he has received consulting fees/honoraria from Prometheus Laboratories.
Stephen A. Boorjian, MD, Panel Member, has disclosed that he has served as a consultant for Ferring Pharmaceuticals Inc. and Merck & Co., Inc.
Jeff M. Michalski, MD, MBA, Panel Member, has disclosed that he has served as a consultant for and received grant/research support from Augmenix, Inc.
Wade J. Sexton, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Arlene O. Siefker-Radtke, MD, Panel Member, has disclosed that she has served as a scientific advisor for Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serano, Genentech, Inc., Janssen Pharmaceutica Products, LP, and Merck & Co., Inc.
Alyse Johnson-Chilla, MS, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.
Lisa A. Gurski, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-18-009-H01-P
All clinicians completing this activity will be issued a certificate of participation.
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation